Cybin
Business Services · Canada · 51-200 Employees
View Company Info for Free
Overview
Headquarters
5600-100 King St W, Toronto, Ontario, M5...Phone Number
(480) 219-7529Website
www.cybin.comRevenue
-Stock Symbol
CYBNIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
2
1
2
1
1
About Cybin
Cybin is a leading ethical biotechnology company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands, and Ireland. The Company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches, and treatment regimens for mental health disorders.Explore more
Cybin Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cybin your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Cybin has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Cybin recently announced quarterly report
Click to see if Cybin had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Cybin has new funding data
Product Launch: Get notified when Cybin launches new products
Congratulate Masked Content for being promoted to Masked Content at Cybin
Cybin, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check out if Cybin is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Cybin
Compare insights from companies similar to Cybin, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Cybin is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Cybin is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Cybin.
Cybin financials insights
Gather financial insights about Cybin, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Share Placement
$30M
2025
Debt
$50M
Cybin Tech Stack
A closer look at the technologies used by Cybin
See more technologies
Most Recent Scoops
Person-Based
Project
Cybin has announced that its commercial strategy for CYB003 focuses on the existing interventional psychiatry infrastructure of ~5000 centers, envisioning it as a day treatment in outpatient clinics for patients with inadequate response to SSRIs/SNRIs.
Pharmaceuticals, Healthcare Operations, Medical Administration
Project
Cybin is developing CYB003, a deuterated psilocin compound, for adjunctive MDD treatment. CYB003 removes the metabolic step compared to naturally occurring psilocin, resulting in a more stable formulation with IP protection.
Research & Development, Medical Research, Pharmaceuticals
Project
reports that CYB003 showed ~14 point MADRS improvement over placebo in Phase 2, with durability of effect out to 12 months seen as a key differentiator compared to typical SSRI improvements.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Research & Development, Pharmaceuticals, Clinical Operations
Cybin News & Media
Cybin Inc. (HELP) Discusses Phase II Results for HLP004 in Generalized Anxiety Disorder Prepared Remarks Transcript
Cybin Inc. (HELP) Discusses Phase II Results for HLP004 in Generalized Anxiety Disorder March 5, 2026 7:30 AM ESTCompany ParticipantsMichael Cola - Chief...Jeffries Highlight Cybin D/B/A Helus Pharma (HELP)’s Science-Driven Psilocybin Therapies as Key Growth Drivers
Cybin D/B/A Helus Pharma (NASDAQ:HELP) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds. The seventh stock on our list of most promising stocks is Cybin D/B/A Helus Pharma (NASDAQ:HELP). TheFly reported on February 2 that Jefferies initiated coverage of HELP with a Buy rating and a $22 price target and also […]Why Cybin (HELP) Is Down 9.1% After Rebranding To Helus And Relisting On Nasdaq
Cybin Inc., now operating as Helus Pharma, has rebranded and moved its U.S. listing from NYSE American to Nasdaq under the ticker HELP, following a previously filed US$100,000,000 at-the-market follow-on equity offering of common shares. The rebranding and Nasdaq inclusion come as the company prepares for potential commercialization of its FDA Breakthrough Therapy-designated Phase 3 candidate HLP003 for major depressive disorder, while also advancing HLP004 for generalized anxiety...
Read more news
Top Business Services Companies
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Cybin
Sign Up For FreeTo access detailed company insights
Cybin is a leading ethical biotechnology company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States... Read More
